ReviewTherapeutic advances in gastroenterology2016
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls.
Review in Therapeutic advances in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Stem cell transplantation for induction of remission in medically refractory Crohn's disease.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- The NLRP3 molecule influences the therapeutic effects of mesenchymal stem cells through Glut1-mediated energy metabolic reprogramming.Journal of advanced research · 2024Article
- Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy.Journal of clinical medicine · 2024Review
- Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease.Inflammopharmacology · 2024Review
- Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells.Current pharmaceutical design · 2024Review
- Therapeutic Potential of Human Intestinal Organoids in Tissue Repair Approaches in Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2023Review
- The role of amino acid metabolism in inflammatory bowel disease and other inflammatory diseases.Frontiers in immunology · 2023Review
- Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results.Human cell · 2021Review
- Gut bioengineering strategies for regenerative medicine.American journal of physiology. Gastrointestinal and liver physiology · 2021Review
- IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGETheranostics · 2020Article
- Mesenchymal Stem Cells-Potential Applications in Kidney Diseases.International journal of molecular sciences · 2019Review
- Human Mesenchymal Stem Cell-Treated Regulatory CD23Theranostics · 2019Article
- The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model.PloS one · 2019Article
- Harnessing Biology to Deliver Therapeutic and Imaging Entities via Cell-Based Methods.Chemistry (Weinheim an der Bergstrasse, Germany) · 2018Review
- Mesenchymal Stem Cells Recruit CCR2Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Expression of Programmed Death-Ligand 1 by Human Colonic CD90Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic, often relapsing, condition that deeply impacts the quality of life for many patients. Although there have been significant advances in medical treatments, a large proportion of patients become refractory to available therapeutic options. Stem-cell therapy through hematopoietic stem cells (HSCs) or mesenchymal stem (stromal) cells (MSCs) is a promising therapeutic option for severe refractory cases especially when surgery is not feasible. In HSC transplantation, the objective is to destroy the 'autoreactive' immune cells responsible for disease chronicity, and to re-establish gut tolerance to gut microbes. In perianal Crohn's disease (CD), the objective is to deposit MSCs locally in fistulizing tracts to down-regulate the local immune response and induce wound healing. Results from upcoming and ongoing clinical trials will set the path of these novel therapeutic options that have the capability to successfully treat severe refractory Crohn's patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.